AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05857241 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fasting mimicking diet (FMD)
Description: D1 will correspond to a pre-fasting phase, with about 800 kcal of intake (approximately 40% of normal caloric intake) from a mono-nutrient diet (fruit, rice or potato according to the patient's preferences). Then D2 and D3 will correspond to the days of actual fasting, with 200-350 kcal of intake (10-18% of normal caloric intake) in the form of 100 ml of broth or vegetable juice (with a teaspoon of linseed oil) three times a day, and vaccination will take place on D4, after returning to a normal diet. 2 to 3 liter of water or unsweetened drink per day is required.Laxatives (unsweetened) will be prescribed and can be taken as during the fasting period.
Study NCT06575465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle nutrition, culture and physical activity workshops
Description: The intervention will include monthly sessions in the community setting of physical activity. In addition, monthly nutrition and culture sessions will be held.
Study NCT06575465 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care patients receive in their primary health care
Study NCT06134375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrathiomolybdate
Description: Tetrathiomolybdate (TM): Ammonium tetrathiomolybdate (TM), an oral copper lowering agent, has been established as safe in patients with Wilson's disease and advanced cancer. TM forms stable copper-molybdenum clusters sequestering copper and thereby limiting its availability, for the proper functioning of angiogenic factors, including secreted metalloenzymes. TM inhibits several copper containing enzymes including ceruloplasmin, cytochrome oxidase, tyrosinase and downregulates cytokines such as MMP9 and VEGF as well as transcription factors such as NF-kB. Both pre-clinical and clinical data suggest that TM may effectively reduce both overt and sub-clinical tumor load by both targeting the metastases initiating stem cell component of primary tumors inactivating Complex IV, shifting oxphos to glycolysis and through stromal remodeling.
Study NCT06134375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000mg/m2 twice daily, Days 1-14 Q21days for 6 months
Study NCT06134375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m2 twice daily, Days 1-14 Q21days for 6 months
Study NCT06134375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: If pembrolizumab was administered in the neoadjuvant setting and the oncology team chooses to continue in the adjuvant setting, standard doses will be used (200 mg IV Q3weeks or 400 mg IV Q6 weeks for one year total as per package insert)
Study NCT06134375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: If pembrolizumab was administered in the neoadjuvant setting and the oncology team chooses to continue in the adjuvant setting, standard doses will be used (200 mg IV Q3weeks or 400 mg IV Q6 weeks for one year total as per package insert)
Study NCT06574984 — intervention group
Intervention type: DRUG
Intervention: Turoctocog alfa
Description: Turoctocog alfa was administered intravenously.
Study NCT05958121 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA402 (Phase Ia)
Description: Intravenous infusions in escalating dose levels
Study NCT05958121 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA402 (Phase Ib)
Description: Treatment at MTD and/or RDE (Phase Ib)
Study NCT05603650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumineux Oral Essentials rinse
Description: mouthrinse
Study NCT05603650 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lumineux Oral Essentials rinse
Description: mouthrinse
Study NCT05603650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listerine rinse
Description: mouthrinse
Study NCT05603650 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Listerine rinse
Description: mouthrinse
Study NCT04763174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Coping Skills Training for Symptom Management (mCOPE)
Description: mCOPE participants will complete 5 videoconferencing sessions (within 5-9 weeks) with a psychologist, each lasting 45-60 minutes, from a location convenient to the patient (e.g., home, work). Sessions will include cognitive behavioral coping skills designed to target pain, fatigue and psychological distress symptoms unique to colorectal cancer patients. mCOPE will include a mobile app for: 1) coping skills content (e.g., audio, video), 2) daily symptoms assessment and coping skills use tracking transmitting in real-time to study staff, and 4) push notifications for reminders, encouragement, and personalized feedback.
Study NCT04711109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Given SC
Study NCT04711109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given SC
Study NCT04711109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04711109 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05958121 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA402 (Phase II)
Description: Treatment at MTD/RDE based on a manageable/favorable safety profile and initial signs of anti-tumor activity of selected ISEC (Phase II)
Study NCT06382870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education
Description: Providing simulation-based training to nurses on child neglect and abuse in the hospital environment
Study NCT04892550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Denneroll traction
Description: The participants will be instructed to lie flat on their back on the ground with their knees slightly bent at 20-30° for comfort and arms gently folded across their stomach. The examiner will position the apex of the Denneroll in one of three regions: lower thoracic (T9-T12), mid-thoracic (T5-T8), and upper-thoracic (T1-T4) depending on the apex of each participant's thoracic kyphosis deformity. For lower thoracic kyphosis (T9-T12) the Denneroll is turned 180° so the peak contacts the lower thoracic spine (T10) while the tapered end supports the mid thoracic region
Study NCT04892550 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal Program
Description: The multimodal program consists of physical pain relief methods, thoracic spine manipulation, myofascial release, and therapeutic exercises.
Study NCT04892550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Program
Description: The multimodal program consists of physical pain relief methods, thoracic spine manipulation, myofascial release, and therapeutic exercises.
Study NCT06575374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir
Description: Given by mouth or intravenously
Study NCT06574139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unstained
Description: Unstained is an individual-level, virtual intervention that involves three \~60-minute sessions delivered over a 3-6 week period. Each session includes watching two videos (six videos total), followed by a discussion facilitated by study coordinators.
Study NCT06574139 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Like
Description: Like is an hour-long film that discusses the impact of social media on the brain. Participants will receive a link to the film and will be asked to watch it independently. The film does not include information related to the outcomes of interest for the study.
Study NCT06481397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ONCObind (Onco-Seraph) 100 Filter
Description: The ONCObind (Onco-Seraph) 100 Microbind® Affinity Blood Filter (Onco-Seraph 100) manufactured by ExThera Medical Corporation in Martinez, CA. The Onco-Seraph 100 filter has been designed and manufactured to reduce residual risks as much as possible to ensure safe usage. Literature search results concluded that heparin coated medical devices are safe and decrease platelet adhesion without affecting the adsorption of major adhesive proteins.~Literature search yielded over 45 publications and 370 treated patients with Seraph platform technology for pathogen removals without significant safety concern. The achieved results from the above-mentioned testing and studies support the performance and safety of Onco-Seraph 100 consistent with the intended use. ExThera Medical concludes that the known and potential benefits of Onco-Seraph 100, when used to treat patients with PDAC, outweigh the known and potential risks when used according to the intended use.
Study NCT06280352 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom made Total Knee Arthroplasty
Description: Total knee replacement, patient specific custom made total knee Origin (Symbios, Symbios Orthopédie SA, Avenue des Sciences 1, 1400 Yverdon-les-Bains, Switzerland)
Study NCT06280352 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Functionally aligned robotically assisted total knee arthroplasty
Description: Total knee replacement, Total Knee Implant Triathlon (Stryker, Kalamazoo, Michigan, U.S.) implanted using MAKO Rio Robotic Arm (Stryker), using functional alignment strategy
Study NCT05931276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol Succinate
Description: a dialyzable, beta-1 selective beta blocker
Study NCT05931276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties
Study NCT05684484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast 500 MCG Oral Tablet [DALIRESP]
Description: Roflumilast has been approved by U.S. Food and Drug Administration (FDA) for attenuating bronchial and dermatological disorders
Study NCT05684484 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: amino salicylic acid
Description: conventional treatment
Study NCT06360354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 193
Description: Administered Orally
Study NCT06360354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV
Study NCT06360354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Administered IV
Study NCT06360354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified FOLFIRINOX
Description: Modified FOLFIRINOX consists of irinotecan, 5-FU, LV, and oxaliplatin administered IV
Study NCT05372484 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multimodal optical imaging
Description: Women referred for colposcopy due to abnormal cervical screening will be recruited into the experimental group of the study. Imaging of study participants will take place during the colposcopy examination.
Study NCT05969483 — intervention group
Intervention type: DEVICE
Intervention: pEEG monitoring
Description: pEEG monitoring during PICU admission
Study NCT05883436 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DEXA-C Cervical Interbody System
Description: The Dexa-C Cervical Interbody System is intended for use on patients who require anterior cervical discectomy and fusion surgery. The system implants an interbody spacer(s) into the cervical intervertebral body space(s) to stabilize and fuse the level(s). Allograft will be used in the spacer and the spinal segment(s) are fixed with an anterior cervical plate
Study NCT04724499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Intervals Training
Description: 16 week exercise program with stationary bike.
Study NCT04724499 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: 16 week stretching program.
Study NCT06297226 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Arlocabtagene Autoleucel (BMS-986393)
Description: Specified dose on specified days
Study NCT06650267 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fathers for Change (F4C)
Description: Defining features of F4C delivered over 18 sessions: 1) focus on the fathers model of fatherhood as a motivator for change, 2) focus on understanding and identifying feelings, teaching skills to identify and change emotional dysregulation that lead to both SU and FV, 3) co-parent communication skills to reduce stress and improve problem solving, 4) restorative parenting (see Table 1 and figure 1)127. F4C focuses on reflective understanding of emotional experiences, how that impacts thoughts and behaviors related to SU, FV, co-parenting/parenting each session. Through greater self-awareness, the father is better able to apply coping, communication and parenting skills introduced to reduce SU and FV.
Study NCT06650267 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Drug Counseling (IDC)
Description: IDC is an individual evidence-based SU treatment84 that incorporates two elements: endorsement of the disease model and the spiritual dimensions of recovery. These elements differentiate the approach from F4C. IDC is influenced by 12-step recovery philosophy and participation in 12-step groups like NA are encouraged. The model places focus on the individual in recovery without a focus on fatherhood or co-parenting. IDC will be offered in an 18-session format.
Study NCT06651333 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: fMRI
Description: Participants will be performing tasks while undergoing fMRI. Tasks include Stroop task, Emotion-regulation task and an Ambiguity reward task, Drug cue task, and Cognitive behavioral therapy task. Participants are not presented with any specific stimulus.
Study NCT04856085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFNα
Description: PEG-IFNα given by subcutaneous injection
Study NCT05405205 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: synbiotic
Description: Consumption of 6 g powder consisting of the strains Lactobacillus fermentum K7-Lb1, L. fermentum K8- Lb1, L. fermentum K11-Lb3, acacia gum (gum arabic), maltodextrin, sucralose and flavour twice a day resolved in drinking water
Study NCT05405205 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic
Description: Consumption of 6 g powder consisting of the strains Lactobacillus fermentum K7-Lb1, L. fermentum K8- Lb1, L. fermentum K11-Lb3, maltodextrin, sucralose and flavour twice a day resolved in drinking water
Study NCT05405205 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Consumption of 6 g powder containing microcrystalline cellulose, maltodextrin , sucralose and flavour twice a day, resolved in drinking water
Study NCT04697524 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support Group Therapy
Description: Virtual group meetings
Study NCT04697524 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom Management Service (SMS) Consultation
Description: Virtual individual meetings with symptom management service (SMS) over 5 minutes
Study NCT04697524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life (QOL) Questionnaires
Description: Administered at each study visit
Study NCT04697524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Virtual exit interview at end of study
Study NCT06179004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: 133mg Liposomal bupivacaine plus 10mL 0.5% bupivacaine administered in a supraclavicular single shot perineural injection
Study NCT06179004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 20mL 0.25% bupivacaine administered in a supraclavicular single shot perineural injection
Study NCT06380309 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IDOV-SAFE
Description: Intravenous injection of oncolytic virus concomitant with Triprolizumab and fruquintinib every 3 weeks until tumor progression
Study NCT05161000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplement
Description: ONS plus dietary counseling
Study NCT05803161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Congrong Runtong oral liquid
Description: Congrong Runtong oral liquid：component total glycosides of Cistanche extracted and refined from the traditional Chinese medicine Cistanche deserticola
Study NCT05803161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placental Congrong Runtong oral liquid
Description: Placental Congrong Runtong oral liquid
Study NCT04639232 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.
Study NCT04639232 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prob-milk
Description: Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.
Study NCT04639232 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Voluntas-Prob
Description: Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.
Study NCT04842630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1916
Description: All participants receive SHR-1906 alone
Study NCT05161000 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dietary counseling
Description: dietary counseling
Study NCT05161000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary counseling
Description: dietary counseling
Study NCT06465550 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BD211
Description: Genetically modified CD34+ autologous stem cells were transfused intravenously with single dosing.
Study NCT06236178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: 1 ml of 40 mg methylprednisolone acetate
Study NCT06236178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Blood
Description: 1 ml of autologous venous blood
Study NCT06152094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BP Activate Letter
Description: Participants in the BP Activate Letter arm will receive a BP Activate Report that includes personalized details about recent measurements, current medications, and computer-generated medication recommendations that might improve your blood pressure, along with a log for tracking additional SMBP measurements. They will also receive a cover letter that includes an assessment that BP appears to be uncontrolled, and suggesting a visit with their provider to discuss.
Study NCT06152094 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Letter
Description: Participants in the Control Letter arm will receive a cover letter that includes an assessment that BP appears to be uncontrolled, and suggesting a visit with their provider to discuss.
Study NCT05906069 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICBT
Description: The intervention will consist in a structured internet-based intervention with 10 modules that will combine cognitive-behavioral techniques to improve obsessive-compulsive symptoms as well as the emotion regulation ability.
Study NCT06027034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online program for psoriasis (GAIA-PSO-01)
Description: The program to-be-tested (GAIA-PSO-01) is an interactive online program for independent use by users with psoriasis. It focuses on recognized treatment elements of cognitive behavioral therapy (CBT) and behavior change techniques.
Study NCT05451303 — intervention group
Intervention type: DEVICE
Intervention: OralViome Cancer Testing System
Description: The OralViome Cancer Testing System is intended for the screening of Oral Squamous Cell Carcinoma (OSCC) and Oropharyngeal cancer (OPC). The system consists of the OralViome Saliva Collection and Transport Kit, the Viome laboratory process for metatranscriptomics, and the Viome analytical software that detects an RNA expression signature within a saliva sample.
Study NCT06236178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local Anesthetic
Description: 1 ml of 2% prilocaine HCl
Study NCT05889247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circulating tumor DNA treatment monitoring
Description: A comparison of treatment monitoring by circulating tumor DNA and CT scans (standard) in patients with newly diagnosed advanced Non-Small Cell Lung Cancer (NSCLC)
Study NCT05320822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Rehab (Group 2)
Description: The Active Rehab protocol builds off of initial chief complaints and duty profile and addresses symptom control followed by a progressive and prescribed integration of activities to full return to duty that should be integrated with the current PRA TBICoE protocols. The specific activity areas in the intervention include low-intensity aerobic exercise that does not exacerbate symptoms, cognition, balance, visual/vestibular, and comfort/ general well-being.~Participants can be progressed daily according to symptom limitations. At least 3-4 sessions each week are recommended based on a trial of sport-related mTBI and other interventions of this type concerning mTBI/concussion. During each phase, low level aerobic exercise that does not significantly exacerbate symptoms, such as nature walks, will be recommended. The additional activity types that may be chosen include cognitive, balance, visual/vestibular, and comfort/general well-being.